IN.PACT Falcon Is the Globally Preferred Drug-Coated Balloon Followed by SeQuent Please and Lutonix Survey Indicates - 19 Action News|Cleveland, OH|News, Weather, Sports

IN.PACT Falcon Is the Globally Preferred Drug-Coated Balloon Followed by SeQuent Please and Lutonix Survey Indicates

Posted:

This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.

SOURCE:

iData Research transcatheter cardiovascular therapeutics global survey results revealed dramatic differences between geographical regions in drug-coated balloon usage trends.

Vancouver, BC (PRWEB) September 04, 2014

According to a recent transcatheter cardiovascular therapeutics global survey conducted by iData Research (http://www.idataresearch.com), the leading global authority in medical device market research, the majority of interventional cardiologists see limited use of drug-coated balloons (DCBs) in conjunction with stenting. However, a significant proportion of respondents employ DCBs regularly, even though it may be reasoned that such usage patterns would differ based on reimbursement levels, survey results show how these patterns may not be the only restricting factor.

Results also suggest a diverse coronary drug-coated balloon usage behavior. In North America 15% of respondents reported the use of drug-coated balloons in overwhelming majority of stent placement procedures. Europes coronary DCBs usage rate however, was surveyed to be a lot less than the similar group in North America.

Price was the most significant consideration in product preference. The price of DCBs was surveyed to be one of the largest drawback and, while this is a global trend, healthcare practitioners in Europe, Asia, Middle East and North America showed the most resistance based on product pricing.

Aside from price, brand preferences played a significant role in a choice-worthy DCB. The IN.PACT Falcon was the globally preferred DCB. In Europe, where DCBs are available, SeQuent® Please was the leading product, and in the U.S., where the devices are awaiting FDA approval, Lutonix® was the leading device that would be used, be over a third of respondents.

Other key findings from the iDatas global transcatheter cardiovascular therapeutics survey:

CoreValve® is the globally preferred device used to perform TAVI procedures, with the exception of North American respondents, where the majority favored SAPIEN.

FFR guidewires make a difference. Respondents who used FFR guidewires used an average of 1.9 fewer stents per procedure and 25% fewer stents overall.

DCBs availability is important. The majority of respondents stated that the availability of devices in their clinic or hospital was the major reason for choosing an FFR guidewire. This was followed by the price of the devices and the clinical outcomes.

For more information
The report for g lobal transcatheter cardiovascular therapeutics survey include end-user attitudes on drug-coated balloons (DCBs), transcatheter heart valve implantation (THVI) and fractional flow reserve (FFR) guidewires. Responses from interventional cardiologists from the United States and 30 other countries were gathered in person at the recent Transcatheter Cardiovascular Therapeutics (TCT) conference. Regions include South America, Europe, Asia, Middle East and North America.

About iData Research
iData Research (http://www.idataresearch.com) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Diabetes Drugs, Diabetes Devices, Pharmaceuticals, Anesthesiology, Wound Management, Orthopedics, Cardiovascular, Ophthalmics, Endoscopy, Gynecology, Urology and more.

For the original version on PRWeb visit: http://www.prweb.com/releases/2014/08/prweb12133958.htm

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

Powered by WorldNow